The initial EMPRISE (Empagliflozin Comparative Effectiveness and Safety) study included patients with T2D from the United States and demonstrated in routine clinical care settings that empagliflozin was associated with a significantly lower risk of hospitalization for heart failure (HHF), all-cause mortality (ACM), cardiovascular mortality (CVM), a composite of MI, stroke, and ACM, when compared with sitagliptin and other dipeptidyl peptidase-4 inhibitors (DPP-4i) [13–15]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.